In order to overcome limitations created by the PD-L1/PD-1 interaction and to reduce the rate of tumor recurrence in these tumors, an immune-based treatment approach targeting PD-1 and CTLA-4 on immune cells and PD-L1 on tumor cells may be beneficial [96, 102] (Figure 1). Here, CD274 is linked to neoplasm.